.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Abstractvortrag
V111

Antitumorale in vitro Synergie von Aprepitant (ein Neurokinin-1-Rezeptor-Antagonist) und 5-ALA in Glioblastom

The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-Aminolevulinic acid in Glioblastoma

Appointment

Date: 26/06/2023

Time: 18:05 – 18:15

Talk time: 7 Min.

Discussion time: 3 Min.

Location / Stream:

C7.2

Session

Neuroonkologie experimentell I

Topic

Neuroonkologie

Authors

Maryam Khaleghi Ghadiri (Münster), Ali Gorji (Münster), Walter Stummer (Münster), Safieh Ebrahimi (Münster)